Higher Risk of VTE With Newer Forms of Oral Contraceptives

Share this content:
Higher Risk of VTE With Newer Forms of Oral Contraceptives
Higher Risk of VTE With Newer Forms of Oral Contraceptives

WEDNESDAY, May 27, 2015 (HealthDay News) -- Newer forms of combined oral contraceptives pills (OCPs) -- brands such as Yaz, Yasmin, and Desogen -- are associated with a higher risk of venous thromboembolism than older versions, according to research published online May 26 in The BMJ.

A team led by Yana Vinogradova, of the University of Nottingham in the United Kingdom, analyzed two large U.K. patient databases. The investigators looked specifically at venous thromboembolism risk among women aged 15 to 49 taking combined OCPs.

The researchers reported that women who used OCPs with newer types of progestogen hormone -- drospirenone, desogestrel, gestodene, and cyproterone -- were 1.5 to 1.8 times more likely to develop venous thromboembolism than those who used OCPs containing older progestogens such as levonorgestrel, norethisterone, and norgestimate. Compared to a control group, those who used the newer OCPs were four times more likely to develop venous thromboembolism, and those who used the older OCPs were 2.5 times more likely to develop venous thromboembolism.

Still, the risk to any one woman remained low. In absolute terms, the extra number of venous thromboembolism cases per year per 10,000 women was six for women using OCPs with levonorgestrel and norgestimate, compared to 14 for those using newer OCPs with desogestrel and cyproterone, the researchers said. Vinogradova's team emphasized that birth control pills are safe, and pointed out that even the three-fold increased risk of venous thromboembolism associated with OCPs is still lower than the 10-fold increased risk that a woman experiences when she is pregnant.

Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »